Forty-eight-week retrospective study of telbivudine and lamivudine treatment in patients with hepatitis B-related cirrhosis

Journal of Viral Hepatitis

Volumn 20, Issue SUPPL.1, 2013, Pages 58-64

  Han, Z ^a   Shi, Y ^a   Zhu, J ^a   Chen, Y ^a   Yin, F ^a   Xia, L ^a   Luo, G ^a   Gao, Z ^a   Liu, J ^a   Jia, G ^a   Li, C ^b   Zhou, X ^a   Han, Y ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

hepatitis B e antigen; hepatitis B virus (HBV) DNA; hepatitis B related cirrhosis; histological improvement; lamivudine; telbivudine

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TELBIVUDINE; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; KIDNEY DYSFUNCTION; KNODELL HISTOLOGIC ACTIVITY INDEX; LACTIC ACIDOSIS; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; NAUSEA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHABDOMYOLYSIS; SCORING SYSTEM; SEROCONVERSION; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; THYMIDINE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84874608229     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12065     Document Type: Article

References (22)

1. Lee W,. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-1745. (Pubitemid 27527771)
2. Lok ASF, McMahon BJ,. Chronic hepatitis B. Hepatology 2001; 34: 1225-1241. (Pubitemid 33096596)
3. Alter MJ,. Epidemiology and prevention of hepatitis B. Semin Liver Dis 2003; 23: 39-46. (Pubitemid 36254661)
4. Vallet-Pichard A, Mallet V, Costentin CE, Pol S,. Treatment of HBV-related cirrhosis. Expert Rev Anti Infect Ther 2009; 7: 527-535.
5. Lok ASF, McMahon BJ,. Chronic hepatitis B: update 2009 (AASLD Practice Guidelines). Hepatology 2009; 50: 1-36.
6. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
7. Antoniou T, Raboud J, Chirhin S, et al,. Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study. HIV Med 2005; 6: 284-290. (Pubitemid 41025294)
8. Marzano A, Marengo A, Marietti M, Rizzetto M,. Lactic acidosis during entecavir treatment in decompensated hepatitis B virus-related cirrhosis. Dig Liver Dis 2011; 43: 1027-1028.
9. Hache C, Villeneuve JP,. Lamivudine treatment in patients with chronic hepatitis B and cirrhosis. Expert Opin Pharmacother 2006; 7: 1835-1843.
10. Liaw YF, Gane E, Leung N, et al,. GLOBE Study Group. Two-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136: 486-495.
11. Lai CL, Leung N, Teo EK, et al,. Telbivudine Phase II Investigator Group. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129: 528-536. (Pubitemid 41096641)
12. Lai CL, Gane E, Liaw YF, et al,. Globe Study Group. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576-2588. (Pubitemid 350294224)
13. Hou J, Yin YK, Xu D, et al,. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology 2008; 47: 447-454. (Pubitemid 351280712)
14. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version). J Hepatol 2003; 38: 533-540.
15. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ,. Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-686. (Pubitemid 43374518)
16. Kronenberger B, Zeuzem S, Sarrazin C, et al,. Dynamics of apoptotic activity during antiviral treatment of patients with chronic hepatitis C. Antivir Ther 2007; 12: 779-787. (Pubitemid 47235492)
17. Hotchkiss RS, Strasser A, McDunn JE, Swanson PE,. Cell death. N Engl J Med 2009; 361: 1570-1583.
18. Farnik H, Lange CM, Hofmann WP, et al,. Nucleos(t)ide analogue treatment reduces apoptotic activity in patients with chronic hepatitis B. J Clin Virol 2011; 52: 204-209.
19. Lau GK, Wang FS,. Uncover the immune biomarkers underlying hepatitis B e antigen (HBeAg) seroconversion: a need for more translational study. J Hepatol 2012; 56: 753-755.
20. Lang T, Lo C, Skinner N, Locarnini S, Visvanathan K, Mansell A,. The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway. J Hepatol 2011; 55: 762-769.
21. Serpaggi J, Carnot F, Nalpas B, et al,. Direct and indirect evidence for the reversibility of cirrhosis. Hum Pathol 2006; 37: 1519-1526. (Pubitemid 44792230)
22. Marcellin P, Heathcote EJ, Buti M, et al,. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-2455.